Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation
Not Applicable
- Conditions
- Severe Mood Dysregulation
- Registration Number
- NCT00825552
- Lead Sponsor
- Federal University of Rio Grande do Sul
- Brief Summary
The purpose of this study is to investigate whether Risperidone is effective in children and adolescents with severe mood dysregulation.
- Detailed Description
Severe Mood Dysregulation(SMD) is a new construct in children and adolescents characterized by persistent and non episodic irritability, hyperarousal and emotional reactivity.
This is an open label trial using Risperidone in children and adolescents( 7-17 years old) diagnosed with SMD.
We hypothesized that Risperidone would improve externalizing symptoms as well as depressive and/or maniac symptomatology. We also consider the effect of the pharmacological intervention in the co-morbid disorders especially ADHD.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Diagnose of Severe Mood Dysregulation
- 7-17 years
- IQ > 70
Exclusion Criteria
- Bipolar disorder
- IQ<70
- Psychosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method We use as the primary outcome the subscale of irritability of the Aberrant Checklist Behavior which measures the intensity of irritability, temper tantruns and hyperarousal symptoms 11/2010
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital de Clinicas de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil